A Video Summary of the Evolution of the RebiSmart® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis

The RebiSmart® electromechanical autoinjector supports people living with relapsing multiple sclerosis to adhere to treatment. In this study, a series of formative usability studies and a final formative study were conducted for the RebiSmart® electromechanical autoinjector. The findings informed the evolution of the next-generation device, RebiSmart® 3.0, which was evaluated in a summative usability study. This animated video provides an overview of this series of studies.

Meet the speaker: Dr Dominic Jack graduated in Manchester, UK with a BSc in Genetics and Molecular Biology in 1993 and subsequently completed a PhD in Immunology at University College London, UK.

After a successful academic career in infectious disease immunology and then with several medical communication agencies, he joined Merck Serono Ltd., Feltham, UK (an affiliate of Merck KGaA) where he acted as the global strategic medical communications lead for pre-launch and launched products within the Neurology and Immunology franchise.

In 2021 Dominic was promoted to the role of Executive Medical Director, providing leadership and strategic direction within Global Medical Affairs.

Original article: Lin YT, Will T, Wickham C et al. Evolution of the RebiSmart® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis. Patient Prefer Adherence. 2023;17:1923-1933. doi:10.2147/PPA.S414151

Click the link in the box below to read the original article.